---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-26-000029"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2026-05-14T12:01:38+00:00"
generated_at: "2026-05-14T12:09:23.414395+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Keros reports Q1 net loss $23.7M; Takeda plans Phase 3 for elritercept in myelofibrosis

## Summary
- Net loss $23.7M in Q1 2026 vs net income $148.5M in Q1 2025 due to prior-year Takeda license revenue.
- R&D expenses fell 67% to $16.1M from $48.7M; transition of elritercept to Takeda and restructuring.
- Cash $281.5M as of Mar 31, 2026; expected funding into first half 2028.
- Takeda plans Phase 3 trial of elritercept for anemia in myelofibrosis, broadening beyond MDS.

## SEC filing metadata
- accession: 0001664710-26-000029
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2026-05-14T12:01:38+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000029/0001664710-26-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000029/kros-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-26-000029
- JSON: https://secwatch.observer/filing/0001664710-26-000029.json
- Plain text: https://secwatch.observer/filing/0001664710-26-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.